WOODBRIDGE, N.J., May 12, 2017 -- EMRISE CORPORATION (formerly traded on OTCQB under the symbol EMRI) (EMRISE or the Company), today announced that the Company expects to make a fourth liquidation dividend distribution to its stockholders totaling approximately $980,000, or $0.09 per share, during the week of June 5, 2017 (the Distribution). When paid, the Distribution will bring the aggregate total of the four liquidation dividends paid to EMRISE stockholders to date to approximately $14.35 million, or $1.32 per share of common stock.
Liquidation dividend distributions are only being made to stockholders of record as of the close of business on July 7, 2015, in connection with the Company’s previously announced voluntary Plan of Dissolution (Plan) that was approved by its stockholders at a special meeting held on June 25, 2015.
The Distribution consists of funds from the sale of the Company’s assets after distributing the prior three liquidation dividends to stockholders; the payment of all obligations to date associated with the Plan; and after deducting the amount the Company believes will be required to pay State and Federal taxes and any remaining costs or liabilities incurred in connection with the dissolution of the Company.
Final Distribution
At this time, EMRISE cannot determine if it can make another liquidation dividend distribution to its stockholders. If made, the amount of any such distribution would depend on a variety of factors including the payment of State and Federal taxes and other costs and liabilities associated with the dissolution of the Company. If EMRISE can make another liquidation dividend distribution to its stockholders, it would be the final such distribution, the amount would be minimal and it would only be made upon completion of the dissolution of the Company, which is currently scheduled to occur in July 2018.
In the future, EMRISE intends to only make public disclosures that are necessary to provide its stockholders with essential information about the status of the Plan.
Other Information
For a detailed description of the Plan and the matters relating to it, stockholders are encouraged to read carefully the Company’s news release dated June 30, 2015, its Form 8-K filed with the Securities and Exchange Commission (SEC) on July 1, 2015, and the Proxy Statement it mailed to stockholders beginning May 11, 2015.
Details of the sale of the Company’s wholly owned Electronic Devices subsidiary in England, EMRISE Electronics Ltd. (EEL), are contained in the Company’s news releases disseminated on June 30, 2015 and March 23, 2015, in its Proxy Statement mailed to stockholders beginning May 11, 2015 and in Forms 8-K filed with the SEC. Details of the sale of CXR-AJ are contained in the Company’s news releases disseminated on February 18, 2016 and December 28, 2015, and in Forms 8-K filed with the (SEC).
Forward Looking Statements
Certain statements in this press release and oral statements made from time to time by representatives of EMRISE regarding the Transaction and the dissolution and liquidation of the Company, the liabilities of EMRISE, the net proceeds anticipated to be available for distribution to the Company’s stockholders, the distribution of funds to stockholders and other matters, all of which are based on information currently available to the Company’s management as well as management’s assumptions and beliefs, are forward-looking statements (“forward-looking statements”) within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For this purpose, any such statements that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements include, without limitation, statements regarding the Company’s expectations, beliefs, or intentions that are signified by terminology such as “subject to,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “estimates,” “may,” “will,” “should,” “can,” the negatives thereof, variations thereon and similar expressions. Such forward-looking statements reflect the Company’s current views with respect to future events, based on what the Company believes are reasonable assumptions; however, such statements are subject to certain risks and uncertainties. Certain of these risks and uncertainties are described in greater detail in EMRISE’s filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or review any forward-looking statements or information, whether as a result of new information, future events or otherwise. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, the Distribution or the Company’s dissolution and related transactions pursuant to the Plan.
CONTACT: DresnerAllenCaron Rene Caron (investors) (949) 474-4300 [email protected]


Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules
European Car Sales Surge in March as EV and Hybrid Demand Accelerates
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast
Meta Expands AI Training With Employee Activity Tracking Tools
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 



